News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
AI based on specific algorithms will scan tens of thousands of approved medications and rare diseases to find potential matches.
PCI congratulates these Penn leaders for their inclusion in the Philadelphia Business Journal's list of "100 business leaders set to shape Philadelphia in 2024."
In an interview with The Philadelphia Inquirer, Swartley explains how in his new role he is hoping to develop a more complete understanding of the broader “definition of what innovation is at Penn."
French company Ceva Santé Animale announced that it is acquiring Scout Bio.
The Penn Center for Innovation (PCI) has announced two key appointments to support the next phase of its comprehensive innovation and commercialization plan.
Penn Medicine's AInSights is a cloud-based machine learning platform accessible by clinicians for real-time image analysis supporting multiple machine learning algorithms.
LilyLoop, which proposed a commercial application for Penn’s biodegradeable moisture sensors, is the winner of the Mack Institute for Innovation Management’s 2024 Y-Prize Competition.
OmnicPath AI specializes in developing an end-to-end workflow that integrates Spatial Transcriptomics (ST) data and high-resolution histology images to predict spatial gene expression.
Weissman has partnered in building 18 mRNA-capable Good Manufacturing Practice (GMP) sites to date across the world.
In 2024, Koo and Steager sat down with Penn Today to discuss this technology’s potential not only to brush teeth, but also to diagnose and treat infectious diseases–in teeth and beyond.